Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | RHEB | Q15382 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602043 | 0.86 | HRH4 (0.81) | HRH4HRH3ALOX15HRH1 | |
| SCHEMBL3369566 | 0.86 | HRH4 (0.59) | HRH4HRH3ALOX15 | |
| SCHEMBL603231 | 0.86 | HRH4 (0.54) | HRH4HRH3ALOX15 | |
| SCHEMBL602139 | 0.84 | HRH4 (0.60) | HRH4HRH3PARP1 | |
| SCHEMBL602123 | 0.81 | HRH4 (0.63) | HRH4HRH3PARP1 | |
| SCHEMBL12353691 | 0.81 | DRD3 (0.53) | HRH4HRH3PARP1 | |
| SCHEMBL16822304 | 0.81 | HRH4 (0.48) | HRH4HRH3ALOX15PTGS2 | |
| SCHEMBL5772728 | 0.81 | HRH4 (0.82) | HRH4HRH3ALOX15 | |
| SCHEMBL6665105 | 0.81 | HRH4 (0.72) | HRH4HRH3PARP1 | |
| Maleic Acid SCHEMBL20162482 | 0.80 | ALOX15 (0.84) | HRH4HRH3ALOX15HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545532-A2 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | claimed |
| US-20040058934-A1 | Heterocyclic compounds | JANSSEN PHARMACEUTIC, N.V. (BE) | 2004-03-25 | — | — | US | claimed |
| WO-2004022060-A2 | (1H-BENZOIMIDAZOL-2-YL)-(PIPERAZINYL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20160000777-A1 | METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF ROCHESTER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | DUNFORD PAUL J | 2009-03-12 | — | — | US | disclosed |
| EP-2010177-A2 | COMBINATION HISTAMINE H1R AND H4R ANTAGONIST THERAPY FOR TREATING PRURITUS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120690-A2 | COMBINATION HISTAMINE H1R AND H4R ANTAGONIST THERAPY FOR TREATING PRURITUS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1545596-A4 | USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-28 | — | — | EP | disclosed |
| EP-1545532-A2 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | disclosed |
| EP-1545596-A2 | USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | disclosed |
| US-20040058934-A1 | Heterocyclic compounds | JANSSEN PHARMACEUTIC, N.V. (BE) | 2004-03-25 | — | — | US | disclosed |
| WO-2004022060-A2 | (1H-BENZOIMIDAZOL-2-YL)-(PIPERAZINYL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004021999-A2 | USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058934-A1 | Heterocyclic compounds | HRH4, HRH2, HRH1 | HRH4 1/4885HRH3 4/4885ALOX15 636/4885 |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | HRH4, HRH2, HRH3 | HRH4 1/4885HRH3 3/4885ALOX15 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.